Granada, Spain
Granada, Spain

The University of Granada is a public university located in the city of Granada that enrolls approximately 80,000 students, thereby becoming the fourth largest university in Spain. UGR also has campuses in Northern Africa , thus being the only European university with campuses in two continents. Founded in 1531 by Emperor Charles V, UGR has almost 500 years of history and it is one of the most famous universities in Spain.According to several rankings, the University of Granada ranks among top ten best Spanish universities and holds first place in Translation and Interpreting studies. In addition, UGR plays a major role in scientific output, placing high in national ranks and being one of the best world universities in computing and mathematics studies. The university has an important heritage thanks to its policy of using buildings of historical and cultural value. The Madrasah of Granada represents one such example. Furthermore, the university has major new facilities committed to innovation, such as the Parque Tecnológico de Ciencias de la Salud.Every year, over 2,000 European students enroll in UGR through the Erasmus Programme, making it the most popular European destination. The university's Center for Modern Languages receives over 10,000 international students each year. UGR also has been recently voted best Spanish university by international students. Wikipedia.


Time filter

Source Type

Patent
Stichting Vumc and University of Granada | Date: 2015-04-21

Disclosed are small ncRNAs that may be used as biomarkers for classifying the health status of an individual. The disclosure also provides screening methods for identifying ncRNA biomarkers.


Patent
Servicio Andaluz De Salud and University of Granada | Date: 2017-02-01

The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.


Patent
Servicio Andaluz De Salud and University of Granada | Date: 2015-03-27

The invention relates to an aqueous melatonin composition exhibiting surprising long-term stability and allowing high concentrations of said water-insoluble active ingredient. The properties of said composition render it useful as an injectable, for example, for the intravenous administration thereof.


The invention relates to the use of microorganisms as plant growth stimulants and for the biological control of bacterium, insects, fungi and phytopathogenic nematodes. More specifically, the invention relates to the use of microorganisms of the genus Bacillus, more specifically the Bacillus methylotrophicus species, as well as to cultures thereof, compositions comprising these bacteria, different culture methods and the products comprising same, as plant growth stimulants and for the biological control of bacterium, insects, fungi and phytopathogenic nematodes.


Patent
University of Granada and Servicio Andaluz De Salud | Date: 2017-06-21

The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.


Patent
Stichting Vumc and University of Granada | Date: 2017-03-08

The present disclosure provides small ncRNAs as biomarkers for classifying the health status of an individual. The disclosure also provides screening methods for identifying ncRNA biomarkers.


Grant
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016

Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses ICT to integrate neuroscience data from around the world, to develop a unified multi-level understanding of the brain and diseases, and ultimately to emulate its computational capabilities. The goal is to catalyze a global collaborative effort. During the HBPs first Specific Grant Agreement (SGA1), the HBP Core Project will outline the basis for building and operating a tightly integrated Research Infrastructure, providing HBP researchers and the scientific Community with unique resources and capabilities. Partnering Projects will enable independent research groups to expand the capabilities of the HBP Platforms, in order to use them to address otherwise intractable problems in neuroscience, computing and medicine in the future. In addition, collaborations with other national, European and international initiatives will create synergies, maximizing returns on research investment. SGA1 covers the detailed steps that will be taken to move the HBP closer to achieving its ambitious Flagship Objectives.


Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in paraplegia from spinal cord ischaemia or even death, particularly for aneurysms extending from the thoracic to the abdominal aorta and thus involving many segmental arteries to the spinal cord, i.e. thoracoabdominal aortic aneurysms of Crawford type II. Although various strategies have achieved a remarkable decrease in the incidence of paraplegia, it is still no less than 10 to 20%. However, it has been found that the deliberate occlusion of the segmental arteries to the paraspinous collateral network finally supplying the spinal cord does not increase rates of permanent paraplegia. A therapeutic option, minimally invasive segmental artery coil embolization has been devised which proceeds in a staged way to occlude groups of arteries under highly controlled conditions after which time must be allowed for arteriogenesis to build a robust collateral blood supply. PAPA-ARTiS is a phase II trial to demonstrate that a staged treatment approach can reduce paraplegia and mortality dramatically. It can be expected to have both a dramatic impact on the individual patients quality of life if saved from a wheelchair, and also upon financial systems through savings in; 1) lower costs in EU health care; 2) lower pay-outs in disability insurance (est. at 500k in Year 1), and; 3) loss of economic output from unemployment. Approx. 2500 patients a year in Europe undergo these high risk operations with a cumulative paraplegia rate of over 15%; therefore >100M per year in costs can be avoided and significantly more considering the expected elimination of type II endoleaks.


Grant
Agency: European Commission | Branch: H2020 | Program: ECSEL-IA | Phase: ECSEL-02-2014 | Award Amount: 139.30M | Year: 2015

The proposed pilot line project WAYTOGO FAST objective is to leverage Europe leadership in Fully Depleted Silicon on Insulator technology (FDSOI) so as to compete in leading edge technology at node 14nm and beyond preparing as well the following node transistor architecture. Europe is at the root of this breakthrough technology in More Moore law. The project aims at establishing a distributed pilot line between 2 companies: - Soitec for the fabrication of advanced engineered substrates (UTBB: Ultra Thin Body and BOx (buried oxide)) without and with strained silicon top film. - STMicroelectronics for the development and industrialization of state of the art FDSOI technology platform at 14nm and beyond with an industry competitive Power-Performance-Area-Cost (PPAC) trade-off. The project represents the first phase of a 2 phase program aiming at establishing a 10nm FDSOI technology for 2018-19. A strong added value network is created across this project to enhance a competitive European value chain on a European breakthrough and prepare next big wave of electronic devices. The consortium gathers a large group of partners: academics/institutes, equipment and substrate providers, semiconductor companies, a foundry, EDA providers, IP providers, fabless design houses, and a system manufacturer. E&M will contribute to the objective of installing a pilot line capable of manufacturing both advanced SOI substrates and FDSOI CMOS integrated circuits at 14nm and beyond. Design houses and electronics system manufacturer will provide demonstrator and enabling IP, to spread the FDSOI technology and establish it as a standard in term of leading edge energy efficient CMOS technology for a wide range of applications battery operated (consumer , healthcare, Internet of things) or not. Close collaboration between the design activities and the technology definition will tailor the PPAC trade-off of the next generation of technology to the applications needs.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 3.99M | Year: 2017

Sustainable Multi-functional Automated Resilient Transport Infrastructures ETN, will bring together a stimulating platform where the stakeholders of the transport infrastructure sector will work alongside world-wide experts in smartening of systems (developers of high-tech sensors, advanced monitoring equipment, automated structures, etc.,) with direct support from the roads, railways and airports managers. This environment will enable talented graduates to conceive the transport infrastructure network of the future and will provide them with world-wide extended training in each of the four pillars supporting the SMARTI vision: designed to last by maximising recycling and minimizing impact (Sustainable), conceived not for transport purposes only and towards optimisation of land use (Multi-functional), equipped for communicating with managers and users, to allow a more intuitive use and a simplified management (Automated), built to be adaptable to natural and anthropogenic hazards (Resilient). The consortium will combine and share expertise to offer advanced scientific training structured into network-wide thematic taught modules combined with original research supported by secondments that will expose fellows to both academia and industry and will also allow them with the possibility to be award with Doctoratus Europeus. The training programme will be enriched by specific modules to support job creation by enabling the fellows with business, entrepreneurship, communication, project management and other transferrable skills. A tailored Dissemination strategy will evaluate the variety of channels and means appropriate to allow the fellows to be prepared and successful in reaching both scientific and larger public audiences. As a result, SMARTI ETN will create a new generation of highly-skilled and appealing professionals that will be in great demand in this rapidly expanding field and will benefit Europe and developing countries

Loading University of Granada collaborators
Loading University of Granada collaborators